DOCSLIB.ORG

Prostate Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prostate Disease Prostate Disease Benign Prostatic Hyperplasia (BPH) Investigations • Urinalysis or midstream urine. The GP’s role • If suspect urinary retention/large post void residual volume. - Ultrasound (Kidneys and bladder). • GPs are typically the first point of contact for men with BPH. - Renal function (Creatinine). • The GP’s role in the management of BPH includes clinical assessment, treatment, referral and follow-up. • PSA: - If suspect prostate cancer (e.g. based on prostate Overview examination) - As part of screening of prostate cancer, after discussion of 1 • BPH is the non-cancerous enlargement of the prostate gland . pros and cons • Whilst not normally life threatening, BPH can impact - Routine PSA screening is not necessary for patients with 2 considerably on quality of life . BPH. Patients with LUTS are not at increased risk of having prostate cancer. Diagnosis PSA levels for different age groups of Western men4 Medical history Age range Serum PSA Serum PSA (ng/mL) • Lower urinary tract symptoms (LUTS). years (ng/mL) median upper limit of normal Urinary symptoms of BPH 40-49 0.7 2.5 Obstructive symptoms: 50-59 1.0 3.5 • Hesitancy 60-69 1.4 4.5 • Weak stream • Post micturition dribble 70-79 2.0 6.5 • Sensation of incomplete bladder emptying. Other PSA tests Overactive symptoms: • PSA velocity or doubling time: if the PSA level doubles in 12-months it may indicate prostate cancer or prostatitis. • Frequency An elevated PSA and a stable velocity suggest BPH. • Urgency (if severe incontinence) -Free-to-total PSA ratio: high ratio (> 25%) suggests BPH; • Nocturia. low ratio (< 10%) suggests prostate cancer. Other: -Prostate Health Index (PHI): not covered by the MBS, PHI • Nocturnal incontinence thought to be more specific for diagnosing prostate cancer than PSA level alone; good quality evidence lacking & • Urinary retention. not recommended in Australian prostate cancer testing. Some men with BPH may not present with many or any symptoms guidelines. of the disease. • Creatinine levels. Symptom score • Post-void residual urine (ultrasound). • Evaluation of symptoms contributes to treatment allocation Investigations by the urologist and response monitoring. • As per GP investigations as indicated +/-. 3 • The International Prostate Symptom Score (IPSS) • Uroflowmetry and post void residual assessment. questionnaire is recommended. • Voiding diary. Physical examination • Cystoscopy. • Digital rectal examination (DRE) can estimate prostate size • Urodynamic assessment. and identify other prostate pathologies. • Basic neurological examination. • Perianal sensation and sphincter tone. • Bladder palpation. • Calibre of the urethral meatus. • Phimosis. Management Surgery Indications for surgery are similar to the indications for referral Observation and review: for mild or low impact symptoms to a urologist. Surgery can be considered when medications are • Optimise through reassurance, education, periodic monitoring no longer suitable for whatever reason. Cessation of medication and lifestyle modifications. therapy usually results in recurrence of symptoms. • Consider adjustment of medication (e.g. timing of diuretic). There are multiple operations available. The gold standard operation is a transurethral resection of the prostate (TURP). Medical therapy: for moderate to severe symptoms There are however numerous operations that are available. Alpha blockers (once daily) Each has their pros and cons. When considering the operation • These are generally 1st line. the patient is undertake there are different factors that are considered such as: - Amsulosin. - Silodosin. • Prostate size/configuration - Alfuzosin. • Anti-coagulation status • Side effects (e.g. preference to preserve antegrade ejaculation) • Side effect profiles may favour tamsulosin. • Day stay vs overnight stay 5α-reductase-inhibitors (5ARIs) • Catheter duration • Dutasteride. • Co-morbidities (long term SPC) • Finasteride. • Durability of operation. Very rarely used as monotherapy. The operations available include: Combination therapy • Transurethral Resection of the Prostate (TURP) • Dutasteride and tamsulosin. • Transurethral Incision of the Prostate (TUIP) • Better for patients with large prostates (> 30 ml). • Green light laser resection of the prostate • 5ARI can affect sexual function so consider carefully in sexually • Minimally invasive insertion of small retractors into prostate active men. • Plasma Vaporisation • Controversy regarding 5ARI association with prostate cancer • Water Vapour therapy risk so recommend PSA surveillance. If PSA increased whilst • Holmium Laser Enucleation of the Prostate (HoLEP). on 5ARI, refer to urologist to exclude prostate cancer. Long term catherisation: Other drugs • Last resort for patients unfit/unwilling for surgery but with Bladder directed medications are most commonly used for complications (e.g. urinary retention) overactive bladder symptoms. • Supra-pubic catheter is preferred to indwelling urethral • Beta-3 adrenergic agonist – Mirabegron. catheter - Requires blood pressure monitoring within first week. • Intermittent Self catheterisation should also be considered • Anticholinergics. in such patients. - Oxybutynin. Follow-up - Solifenacin. • It is appropriate for the GP to monitor and follow-up a patient - Darifenacin. with respect to all the treatment modalities. However, if the • Side effects include dry mouth, dry eyes and/or constipation. patient is not responding to medical treatment, refer to the urologist. Urologist referral • Men who have had TURP remain at risk for prostate cancer and need routine prostate cancer checks, as per guidelines. Treatment • Urinary retention history. Recommended follow-up timeline after BPH treatment • Urinary tract infection. Treatment First year after Annually • Haematuria. modality treatment thereafter • Failed medical therapy. 6 12 6 • Incontinence (of any type). weeks weeks months • Post void residual of > 100 ml. Observation and review X X • Severe symptoms (especially if poorly responsive 5α-reductase inhibitors X to medications). • Renal impairment. α-blockers X • Bladder stones. Surgery or minimal invasive treatment • Cancer suspected — prostate or bladder. • Associated Neurological condition (e.g. Parkinson’s disease, Multiple sclerosis). Prostatitis Chronic nonbacterial prostatitis (chronic prostate pain syndrome); treatment is difficult and cure is often not possible. The GP’s role Treatment focus is on symptom management, to improve quality of life. Non-medical therapy is recommended as the initial • GPs are typically the first point of contact for men with treatment. prostatitis. Medication options5 • The GP’s role in the management of prostatitis includes clinical • α-blockers. assessment, treatment, referral and follow-up. - Suited to patients with moderate/severe LUTS. Overview - Tamsulosin. - Silodosin. • Prostatitis is inflammation of the prostate gland. - Alfuzosin. • It can be a result of bacterial or non-bacterial infection. - Side effect profiles may favour tamsulosin. • Acute bacterial prostatitis, the least common form, can be • Antibiotics (not all antibiotics penetrate the prostate gland). serioius if the infection is left untreated. - Recommend: Norfloxacin, Ciprofloxacin, Trimethoprim, • Whilst not normally life threatening, prostatitis can impact Sulphamethoxazole/Trimethoprim, Erythromycin, Gentamicin. considerably on a man’s quality of life. - Young men with confirmed Chlamydia prostatitis: Doxycycline. Diagnosis • Analgesics. Medical history • Non-steroidal anti-inflammatory drugs. • Urinary symptoms. Surgical options • Pain. • Transurethral incision of the bladder neck. Symptoms of prostatitis • Transurethral resection of the prostate. • Dysuria — painful urination. Surgery has a very limited role and requires an additional, specific indication (e.g. prostate obstruction, prostate calcification). • Urgent need to urinate. • Frequent urination. Other options • Painful ejaculation. • Lifestyle changes: avoid activity that involves vibration or • Lower back pain. trauma to the perineum (e.g. bike riding, tractor driving, long- • Perineal pain. distance driving, cut out caffeine, spicy foods, alcohol, avoid constipation). • Chills and/or fever. • Some patients may benefit from treatment by a specialised • Muscular pain. pelvic floor physiotherapist, which may include pelvic floor • General lack of energy. relaxation techniques and trigger point massage. Investigations • Prostate massage. • Digital rectal examination (DRE): • Supportive therapy: biofeedback, relaxation exercises, acupuncture, massage therapy, chiropractic therapy - Should not be performed if you suspect acute severe and meditation. prostatitis because it can be very painful • Heat therapy. - Some tenderness and swelling may accompany sub-acute prostatitis. Referral • Prostate specific antigen (PSA) levels: Indicators for referral to a urologist - Levels may be dramatically high • When the GP is not confident in managing the condition. - PSA velocity: if the PSA level doubles in 12-months it may indicate prostate cancer or prostatitis. • If the GP is concerned there are other potential diagnoses, particularly prostate or bladder cancer. • Urine analysis: • Those who do not respond to initial first-line therapy such as - First pass urine: Chlamydia urine PCR test antibiotics and/or α-blockers. For these patients, more invasive - Midstream urine: MC&S investigations, such as cystoscopy and transrectal prostate - Urine PCR for STIs should be done if Chlamydia or other ultrasound scan,
Load more

Recommended publications
  • Departmentof UROLOGY
    DEPARTMENT of UROLOGY UPDATE New Treatments for Benign Prostatic Hyperplasia Expanded Choices Provide Relief for a Common Condition FALL 2008 Vol.19 | No.2 The symptoms of an enlarged prostate include a weak stream, trouble starting and gland, called benign prostatic hyper- stopping, the frequent feeling of needing to Clinical Update p. 4 plasia (BPH), are familiar to a substantial urinate, and the sense that the bladder isn’t Kidney Cancer Vaccine p. 5 proportion of men older than 50. empty after urination. About half of men in their 50s and 80-90 percent Erectile Dysfunction Research p. 5 “To some degree, BPH affects all men as they of those older than 80 have enlarged prostates, age,” says Allan Pantuck, MD, MS, associate Clinical Trials p. 6 caused by changes in hormone balance and cell professor and physician in the UCLA Integrative growth. As their prostate begins to squeeze or Profile: Oscar Rivera, LVN p. 8 Urology Program, which combines the best partially block the surrounding urethra — the of preventative approaches, medical counseling, Kudos p. 9 tube that carries the urine from the bladder out nutritional science, and complementary medical of the body — many of these men experience Donor Notes p. 9 approaches for patients interested in the bothersome urinary symptoms, which can prevention and treatment of urologic conditions. Profile: Arthur Schapiro p. 9 “The prostate forms a channel that the urine passes through as it comes out of the bladder. As the prostate enlarges, there is increased resistance to the bladder’s ability to empty. This tends to also lead to changes in the bladder, including a decreased ability to hold urine.” BPH can wreak havoc with quality of life — in addition to the discomfort, some men are forced to get up several times during the night.
    [Show full text]
  • GERONTOLOGICAL NURSE PRACTITIONER Review and Resource M Anual
    13 Male Reproductive System Disorders Vaunette Fay, PhD, RN, FNP-BC, GNP-BC GERIATRIC APPRoACH Normal Changes of Aging Male Reproductive System • Decreased testosterone level leads to increased estrogen-to-androgen ratio • Testicular atrophy • Decreased sperm motility; fertility reduced but extant • Increased incidence of gynecomastia Sexual function • Slowed arousal—increased time to achieve erection • Erection less firm, shorter lasting • Delayed ejaculation and decreased forcefulness at ejaculation • Longer interval to achieving subsequent erection Prostate • By fourth decade of life, stromal fibrous elements and glandular tissue hypertrophy, stimulated by dihydrotestosterone (DHT, the active androgen within the prostate); hyperplastic nodules enlarge in size, ultimately leading to urethral obstruction 398 GERONTOLOGICAL NURSE PRACTITIONER Review and Resource M anual Clinical Implications History • Many men are overly sensitive about complaints of the male genitourinary system; men are often not inclined to initiate discussion, seek help; important to take active role in screening with an approach that is open, trustworthy, and nonjudgmental • Sexual function remains important to many men, even at ages over 80 • Lack of an available partner, poor health, erectile dysfunction, medication adverse effects, and lack of desire are the main reasons men do not continue to have sex • Acute and chronic alcohol use can lead to impotence in men • Nocturia is reported in 66% of patients over 65 – Due to impaired ability to concentrate urine, reduced
    [Show full text]
  • Management of Male Lower Urinary Tract Symptoms (LUTS), Incl
    Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) M. Oelke (chair), A. Bachmann, A. Descazeaud, M. Emberton, S. Gravas, M.C. Michel, J. N’Dow, J. Nordling, J.J. de la Rosette © European Association of Urology 2013 TABLE OF CONTENTS PAGE 1. INTRODUCTION 6 1.1 References 7 2. ASSESSMENT 8 3. CONSERVATIVE TREATMENT 9 3.1 Watchful waiting - behavioural treatment 9 3.2 Patient selection 9 3.3 Education, reassurance, and periodic monitoring 9 3.4 Lifestyle advice 10 3.5 Practical considerations 10 3.6 Recommendations 10 3.7 References 10 4. DRUG TREATMENT 11 4.1 a1-adrenoceptor antagonists (a1-blockers) 11 4.1.1 Mechanism of action 11 4.1.2 Available drugs 11 4.1.3 Efficacy 12 4.1.4 Tolerability and safety 13 4.1.5 Practical considerations 14 4.1.6 Recommendation 14 4.1.7 References 14 4.2 5a-reductase inhibitors 15 4.2.1 Mechanism of action 15 4.2.2 Available drugs 16 4.2.3 Efficacy 16 4.2.4 Tolerability and safety 17 4.2.5 Practical considerations 17 4.2.6 Recommendations 18 4.2.7 References 18 4.3 Muscarinic receptor antagonists 19 4.3.1 Mechanism of action 19 4.3.2 Available drugs 20 4.3.3 Efficacy 20 4.3.4 Tolerability and safety 21 4.3.5 Practical considerations 22 4.3.6 Recommendations 22 4.3.7 References 22 4.4 Plant extracts - Phytotherapy 23 4.4.1 Mechanism of action 23 4.4.2 Available drugs 23 4.4.3 Efficacy 24 4.4.4 Tolerability and safety 26 4.4.5 Practical considerations 26 4.4.6 Recommendations 26 4.4.7 References 26 4.5 Vasopressin analogue - desmopressin 27 4.5.1
    [Show full text]
  • Prostatitis Explained Prostatitis
    Prostate information Prostatitis Explained Prostatitis Prostatitis (prost-a-ty-tus) is the most common prostate problem for men under 50, but it can affect men of all ages. In fact, almost 1 out of 2 men between 18 and 50 may have at least one bout of prostatitis in their lifetime. Prostatitis is often described as an infection of the prostate but it can also mean that the prostate is inflammed or irritated. If you have prostatitis, you may have a burning feeling when passing urine, pass urine more often, be in a lot of pain, have a fever and chills and feel very tired. Once your doctor has diagnosed your symptoms as prostatitis, then the outlook tends to be good. There are many treatments available and your doctor will work with you to find the treatment(s) most suitable for you depending on the type of prostatitis you have. So, it may take slightly longer for some men to see an improvement in their symptoms. However, even when you feel your symptoms are starting to improve you should still continue with your treatment or medication. It may be reassuring to know that prostatitis is neither connected with cancer nor does it mean there is an increased risk of developing prostate cancer in the future, but it can cause worrying symptoms. Table of contents Page Types of prostatitis 3 Acute bacterial prostatitis 5 Chronic bacterial prostatitis 8 Chronic pelvic pain syndrome 9 Treatment for CBP and CPPS 13 Coping with pain 14 Tips to relieve prostatitis 16 Prostatitis There are different types of prostatitis.
    [Show full text]
  • Phimosis Table of Contents
    Information for Patients English Phimosis Table of contents What is phimosis? ................................................................................................. 3 How common is phimosis? ............................................................................. 3 What causes phimosis? ..................................................................................... 3 Symptoms and Diagnosis ................................................................................. 3 Treatment ................................................................................................................... 4 Topical steroid .......................................................................................................... 4 Circumcision .............................................................................................................. 4 How is circumcision performed? .................................................................. 4 Recovery ...................................................................................................................... 5 Paraphimosis ........................................................................................................... 5 Emergency treatment ....................................................................................... 5 Living with phimosis ........................................................................................... 5 Glossary ................................................................................... 6 This information
    [Show full text]
  • Chronic Bacterial Prostatitis Treated with Phage Therapy After Multiple Failed Antibiotic Treatments
    CASE REPORT published: 10 June 2021 doi: 10.3389/fphar.2021.692614 Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments Apurva Virmani Johri 1*, Pranav Johri 1, Naomi Hoyle 2, Levan Pipia 2, Lia Nadareishvili 2 and Dea Nizharadze 2 1Vitalis Phage Therapy, New Delhi, India, 2Eliava Phage Therapy Center, Tbilisi, Georgia Background: Chronic Bacterial Prostatitis (CBP) is an inflammatory condition caused by a persistent bacterial infection of the prostate gland and its surrounding areas in the male pelvic region. It is most common in men under 50 years of age. It is a long-lasting and Edited by: ’ Mayank Gangwar, debilitating condition that severely deteriorates the patient s quality of life. Anatomical Banaras Hindu University, India limitations and antimicrobial resistance limit the effectiveness of antibiotic treatment of Reviewed by: CBP. Bacteriophage therapy is proposed as a promising alternative treatment of CBP and Gianpaolo Perletti, related infections. Bacteriophage therapy is the use of lytic bacterial viruses to treat University of Insubria, Italy Sandeep Kaur, bacterial infections. Many cases of CBP are complicated by infections caused by both Mehr Chand Mahajan DAV College for nosocomial and community acquired multidrug resistant bacteria. Frequently encountered Women Chandigarh, India Tamta Tkhilaishvili, strains include Vancomycin resistant Enterococci, Extended Spectrum Beta Lactam German Heart Center Berlin, Germany resistant Escherichia coli, other gram-positive organisms such as Staphylococcus and Pooria Gill, Streptococcus, Enterobacteriaceae such as Klebsiella and Proteus, and Pseudomonas Mazandaran University of Medical Sciences, Iran aeruginosa, among others. *Correspondence: Case Presentation: We present a patient with the typical manifestations of CBP.
    [Show full text]
  • Sexually Transmitted Infections Treatment Guidelines, 2021
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized
    [Show full text]
  • EAU-Guidelines-On-Paediatric-Urology-2019.Pdf
    EAU Guidelines on Paediatric Urology C. Radmayr (Chair), G. Bogaert, H.S. Dogan, R. Kocvara˘ , J.M. Nijman (Vice-chair), R. Stein, S. Tekgül Guidelines Associates: L.A. ‘t Hoen, J. Quaedackers, M.S. Silay, S. Undre European Society for Paediatric Urology © European Association of Urology 2019 TABLE OF CONTENTS PAGE 1. INTRODUCTION 8 1.1 Aim 8 1.2 Panel composition 8 1.3 Available publications 8 1.4 Publication history 8 1.5 Summary of changes 8 1.5.1 New and changed recommendations 9 2. METHODS 9 2.1 Introduction 9 2.2 Peer review 9 2.3 Future goals 9 3. THE GUIDELINE 10 3.1 Phimosis 10 3.1.1 Epidemiology, aetiology and pathophysiology 10 3.1.2 Classification systems 10 3.1.3 Diagnostic evaluation 10 3.1.4 Management 10 3.1.5 Follow-up 11 3.1.6 Summary of evidence and recommendations for the management of phimosis 11 3.2 Management of undescended testes 11 3.2.1 Background 11 3.2.2 Classification 11 3.2.2.1 Palpable testes 12 3.2.2.2 Non-palpable testes 12 3.2.3 Diagnostic evaluation 13 3.2.3.1 History 13 3.2.3.2 Physical examination 13 3.2.3.3 Imaging studies 13 3.2.4 Management 13 3.2.4.1 Medical therapy 13 3.2.4.1.1 Medical therapy for testicular descent 13 3.2.4.1.2 Medical therapy for fertility potential 14 3.2.4.2 Surgical therapy 14 3.2.4.2.1 Palpable testes 14 3.2.4.2.1.1 Inguinal orchidopexy 14 3.2.4.2.1.2 Scrotal orchidopexy 15 3.2.4.2.2 Non-palpable testes 15 3.2.4.2.3 Complications of surgical therapy 15 3.2.4.2.4 Surgical therapy for undescended testes after puberty 15 3.2.5 Undescended testes and fertility 16 3.2.6 Undescended
    [Show full text]
  • Reference ID: 4555351 See 17 for PATIENT COUNSELING INFORMATION and Medication Guide
    HIGHLIGHTS OF PRESCRIBING INFORMATION 5 mg dapagliflozin/1000 mg metformin HCl extended-release (3) These highlights do not include all the information needed to use 10 mg dapagliflozin/500 mg metformin HCl extended-release (3) XIGDUO XR safely and effectively. See full prescribing information for 10 mg dapagliflozin/1000 mg metformin HCl extended-release (3) XIGDUO XR. ------------------------------ CONTRAINDICATIONS ----------------------------- ® XIGDUO XR (dapagliflozin and metformin HCl extended-release) Severe renal impairment: (eGFR below 30 mL/min/1.73 m2), end-stage tablets, for oral use renal disease or dialysis. (4, 5.1) Initial U.S. Approval: 2014 History of serious hypersensitivity to dapagliflozin or hypersensitivity to metformin HCl. (4, 6.1) WARNING: LACTIC ACIDOSIS Metabolic acidosis, including diabetic ketoacidosis. (4, 5.1) See full prescribing information for complete boxed warning. ----------------------- WARNINGS AND PRECAUTIONS ---------------------- Postmarketing cases of metformin-associated lactic acidosis have Lactic Acidosis: See boxed warning (2.3, 4, 5.1) resulted in death, hypothermia, hypotension, and resistant Hypotension: Before initiating XIGDUO XR, assess and correct volume bradyarrhythmias. Symptoms included malaise, myalgias, status in the elderly, patients with renal impairment or low systolic blood respiratory distress, somnolence, and abdominal pain. Laboratory pressure, and in patients on diuretics. Monitor for signs and symptoms abnormalities included elevated blood lactate levels, anion gap during therapy. (5.2, 6.1) acidosis, increased lactate/pyruvate ratio; and metformin plasma Ketoacidosis: Assess patients who present with signs and symptoms of levels generally >5 mcg/mL. (5.1) metabolic acidosis for ketoacidosis regardless of blood glucose level. If Risk factors include renal impairment, concomitant use of certain suspected, discontinue XIGDUO XR, evaluate and treat promptly.
    [Show full text]
  • A Systematic Review and Meta-Analysis Lei Zhang1*, Yi Wang1*, Zhiqiang Qin2*, Xian Gao3, Qianwei Xing4, Ran Li1, Wei Wang1, Ninghong Song1, Wei Zhang1
    Journal of Cancer 2020, Vol. 11 177 Ivyspring International Publisher Journal of Cancer 2020; 11(1): 177-189. doi: 10.7150/jca.37235 Research Paper Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis Lei Zhang1*, Yi Wang1*, Zhiqiang Qin2*, Xian Gao3, Qianwei Xing4, Ran Li1, Wei Wang1, Ninghong Song1, Wei Zhang1 1. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210009, China. 2. Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. 3. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210009, China. 4. Department of Urology, The Affiliated Hospital of Nantong University, Nantong, 226001, China. *These authors contributed equally to this work. Corresponding authors: Wei Zhang, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, China. E-mail: [email protected], TEL: +08613901595401; Qianwei Xing, Department of Urology, The Affiliated Hospital of Nantong University, Nantong, 226001, China. E-mail: [email protected], TEL: +08615240552009. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.06.02; Accepted: 2019.09.27; Published: 2020.01.01 Abstract Background: No consensus has been reached on the definite associations among prostatitis, benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Hence, this meta-analysis was conducted to explore their triadic relation by summarizing epidemiological evidence. Methods: Systematical and comprehensive retrieval of online databases PubMed, PMC, EMBASE and Web of Science was performed to acquire eligible studies, up to April 1st, 2019.
    [Show full text]
  • Risk Factors for Squamous Cell Carcinoma of the Penis— Population-Based Case-Control Study in Denmark
    2683 Risk Factors for Squamous Cell Carcinoma of the Penis— Population-Based Case-Control Study in Denmark Birgitte Schu¨tt Madsen,1 Adriaan J.C. van den Brule,2 Helle Lone Jensen,3 Jan Wohlfahrt,1 and Morten Frisch1 1Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark; 2Department of Pathology, VU Medical Center, Amsterdam and Laboratory for Pathology and Medical Microbiology, PAMM Laboratories, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands;and 3Department of Pathology, Gentofte University Hospital, Niels Andersens Vej 65, Hellerup, Denmark Abstract Few etiologic studies of squamous cell carcinoma female sex partners, number of female sex partners (SCC) of the penis have been carried out in populations before age 20, age at first intercourse, penile-oral sex, a where childhood circumcision is rare. A total of 71 history of anogenital warts, and never having used patients with invasive (n = 53) or in situ (n = 18) penile condoms. Histories of phimosis and priapism at least 5 SCC, 86 prostate cancer controls, and 103 population years before diagnosis were also significant risk controls were interviewed in a population-based case- factors, whereas alcohol abstinence was associated control study in Denmark. For 37 penile SCC patients, with reduced risk. Our study confirms sexually tissue samples were PCR examined for human papil- transmitted HPV16 infection and phimosis as major lomavirus (HPV) DNA. Overall, 65% of PCR-examined risk factors for penile SCC and suggests that penile- penile SCCs were high-risk HPV-positive, most of oral sex may be an important means of viral transmis- which (22 of 24; 92%) were due to HPV16.
    [Show full text]
  • Erection Disorders
    CHAPTER 11 ERECTION DISORDERS Despite the current rhetoric. about sex and intimacy’s involving more than penile-vaginal inter- course, the quest for a rigid erection appears to dominate both popular and professional interest. More- over, it seems likely that our diligence in finding new ways for overcoming erectile difficulties serves unwittingly to reinforce the male myth that rock-hard, ever-available phalluses are a necessary compo- nent of male identity. This is indeed a dilemma. 1 ROSEN AND LEIB L UM , 1992 GENE R A L CONSIDE R ATIONS The Problem A 49-year-old widower described erection difficulties for the past year. His 25-year marriage was loving and harmonious throughout but sexual activity stopped after his wife was diagnosed with ovarian cancer six years before her death. Their sexual relationship during the period of her illness had been meager as a result of her lack of sexual desire. Although he missed her greatly, he felt lonely since her death three years before and, somewhat reluctantly at first, began dating other women. A resumption of sexual activity soon resulted but much to his chagrin he found that in contrast to when he would awaken in the morning or masturbate, his erections with women partners were much less firm. He felt considerable tension, particu- larly because some months before, he had developed a strong attachment to one woman in particular and was fearful that the relationship would soon end because of his sexual troubles. As he discussed his grief over the loss of his wife and talked about his guilt over his intimacy with another woman, his erectile problems began to diminish.
    [Show full text]